SLC5A2 and type 2 diabetes mellitus: Larger and longer studies are required to confirm the effectiveness of combined SGLT1/SGLT2 inhibition in reducing MI and stroke in patients with type 2 diabetes and elucidate the mechanisms associated with this finding.